Építés alatt – nem éles oldal
Belépés
Befejeződött1. fázis

Safety and Tolerability of F012 in Patients With Hyperuricemia and Gout

A legfontosabb adatok

Ki végzi
The Affiliated Hospital of Qingdao University
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
1. fázis
Résztvevők
40 fő vett részt
Kezdés
2024. jún. 11.
Befejezés
2025. nov. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • PEGylated uricase
  • F012 placebo
A regiszteradat frissítve
2026. november 16.

Ki vehet részt

Életkor
18 év – 60 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 31 feltétel megnézéseKevesebb

Ki vehet részt

  • Hyperuricemia patients: Stop uric acid lowering treatment for more than 7 days, and take two non same day treatments within 7 days.Fasting blood uric acid level ≥ 480 μ mol/L
  • Patients with or without occasional gout: Complies with the 2015 American College of Rheumatology ACR/European Union Against Rheumatism (EULAR) jointly launch diagnosis of gout standardized and screened with less than 2 gout attacks in the previous year
  • The weight of male subjects is ≥ 50.0kg, and the weight of female subjects is ≥ 45.0kg. Weight refers toBMI is between 18~30kg/m2, including the critical value
  • The subjects have a good daily routine and are able to maintain good communication and compliance with the researchersAdhere to various requirements of clinical trials
  • Voluntarily sign the informed consent form

Ki nem vehet részt

  • Those with a history of tuberculosis within 6 months before screening
  • Organ transplant patients
  • History of acute gout attacks within 2 weeks prior to the screening period or being in the acute gout attack phase at the time of screening
  • Individuals who have previously received uricase therapy
  • Individuals with herpes zoster infection, uncorrected dehydration, acidosis, or currently using nephrotoxic drugs
  • Those who have undergone surgical procedures within 3 months prior to the first administration, or plan to undergo surgical procedures during the study period
  • Individuals who have received any other clinical trial drug/device treatment within 3 months prior to the first administration
  • Those who consume more than 1L of strong tea, coffee, and/or caffeinated beverages per day within the first 3 months prior to the first administration; Eating high purine foods (such as animal organs, seafood, etc.) within 48 hours before administration
  • Individuals who donate blood or experience significant blood loss (≥ 400mL, excluding normal menstrual blood loss in females), receive blood transfusions, or use blood products within 3 months prior to the first administration of medication
  • Smoking ≥ 5 cigarettes per day within 3 months before the first administration, or unwilling to ban any tobacco products during the trial period
  • Positive alcohol breath test results, or those who have been drinking alcohol for more than 14 units per week within the past 3 months before the first administration (1 unit of alcohol equals approximately 285mL of beer, 25mL of strong liquor, or 100mL of wine)
  • Individuals with a history of drug abuse (including repeated and excessive use of various types of narcotics and psychotropic drugs for non-medical purposes) or positive drug abuse screening results within one year prior to the first administration
  • Individuals who have received inactivated vaccines within one month prior to the first dose, received live/attenuated vaccines within three months prior to the first dose, or plan to receive any vaccines during the trial period
  • Female subjects who engage in unprotected sexual activity during pregnancy, lactation, or 2 weeks prior to administration, as well as those who have a pregnancy plan or a plan to donate sperm or eggs within 6 months after the end of the trial and are unwilling to use a medically recognized contraceptive method (such as intrauterine devices or condoms) or abstain during the trial period
  • Malignant tumor patients
  • Individuals with drug allergies
  • Individuals with clear blood system disorders or abnormal coagulation function
  • Virological tests show positive results for HCV antibodies, HIV antibodies, and Treponema pallidum antibodies; HBV: HBsAg and/or HBcAb positive individuals with HBV-DNA above the upper limit of normal values
  • Individuals with severe mental and psychological disorders, cognitive impairments, and a history of mental illness
  • Individuals with a tendency to bleed, such as those who experience bleeding or subcutaneous bleeding due to mild collisions during normal times
  • People who have difficulty with venipuncture, cannot tolerate venipuncture, and have a history of needle and blood dizziness
  • Individuals with a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency or abnormal G6PD with clinical significance, history of catalase deficiency, history of autoimmune diseases, and history of atopic allergic diseases
  • Patients with unstable angina pectoris, serious arrhythmia requiring drug intervention, congestive heart failure [NYHA rating ≥ Grade II], uncontrolled hypertension (more than 150/95 mmHg), poor blood glucose control in diabetes patients (i.e. glycosylated hemoglobin HbA1c ≥ 7%), acute stroke, severe or chronic hemorrhagic digestive system disease, pleural effusion, abdominal effusion, etc
  • Individuals with creatinine levels greater than 1.5 times the upper limit of normal; Individuals with serum transaminase levels exceeding 1.5 times the upper limit of normal range
  • Patients with secondary hyperuricemia
  • Those who may not be able to complete this study due to other reasons or who the researcher deems should not be included

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is a randomized, double-blind, placebo-controlled single dose escalation (SAD) study conducted in patients with hyperuricemia with or without gout. The plan is to conduct ramp ups in 5 dose groups of 1mg, 2mg, 4mg, 6mg, and 8mg (adjustable during the study), with 8 subjects in each dose group and a total of 40 subjects. The sentinel method will be used for each dose group, with 2 subjects in the first group (1A+1P) followed by 6 subjects in the second group (5A+1P), to observe safety and tolerability.

A vizsgálat 2 csoportja

  • Placebo groupPlacebo, összehasonlításként

    Single intravenous injection of placebo

    Kezelés: F012 placebo

  • F012 experimental groupA vizsgált kezelés

    Single intravenous injection of F012

    Kezelés: PEGylated uricase

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Phase I Clinical Study Evaluating the Safety and Tolerability of F012 in Patients With Hyperuricemia and Gout
A regiszteradat frissítve
2026. november 16.